John Wilding

John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05).

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

In this video interview, diabetes specialist John Wilding discusses how the CREDENCE trial findings may impact the treatment of people with type 2 diabetes and chronic kidney disease (3:31).

John Wilding discusses the implications of the 2-year outcomes of the DiRECT trial, and the questions that remain unanswered (4:17).

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the treatment of sight-threatening retinopathy and maculopathy in people with diabetes (9:11).

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the disease processes that lead to retinopathy in people with diabetes (9:11).

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss diabetic retinopathy screening and the key role that it plays in reducing vision loss among people with diabetes (10:00).

Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

John Wilding discusses the unexpected results of HARMONY, the albiglutide cardiovascular outcomes study (2:43).

John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)

Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines (9:43).

John Wilding explains how the latest update of the nutrition guidelines will help clinicians working with patients with obesity (1:53).

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.